Starling Oncology, Inc. (STLN) Stock Analysis
A live, multi-source view of Starling Oncology, Inc. (STLN): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Starling Oncology, Inc.
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Sector: Healthcare · Industry: Medical Care Facilities · United States · 641 employees · starlingoncology.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Starling Oncology, Inc. (STLN) had a market capitalization of $604.4M and a beta of 0.44; the shares traded in a 52-week range of $2.32 – $7.05 (82.5% over the year).
- Market cap
- $604.4M
- Enterprise value
- $668.1M
- EPS (trailing)
- $-0.29
- Payout ratio
- 0.0%
- 52-week range
- $2.32 – $7.05
- 52-week change
- 82.5%
- Beta
- 0.44
- Average volume
- 1.8M
- Shares outstanding
- 101.9M
- Short % of float
- 7.68%
- Profit margin
- -6.2%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Starling Oncology, Inc. (STLN) last closed at $6.29 (the last completed close before that scan).
Technicals at the scan: RSI 55 (neutral territory), price +0.3% versus its 20-day average, 20-day versus 50-day average spread +8.5%, MACD histogram -0.04.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 80/100.
Next scheduled company event: in 60 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of STLN; corporate insiders filed 1 buy and 1 sell (2 distinct filers, latest disclosure 2026-08-24). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Brad Hively (0B/1S), Jorey Chernett (1B/0S). Who is trading what
RapidTradeView pick record
STLN has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Starling Oncology, Inc. (STLN) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell STLN.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.